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Using a Non-Image-Based Medium-Throughput Assay for
Screening Compounds Targeting N-myristoylation in
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Abstract
We have refined a medium-throughput assay to screen hit compounds for activity against N-myristoylation in intracellular
amastigotes of Leishmania donovani. Using clinically-relevant stages of wild type parasites and an Alamar blue-based
detection method, parasite survival following drug treatment of infected macrophages is monitored after macrophage lysis
and transformation of freed amastigotes into replicative extracellular promastigotes. The latter transformation step is
essential to amplify the signal for determination of parasite burden, a factor dependent on equivalent proliferation rate
between samples. Validation of the assay has been achieved using the anti-leishmanial gold standard drugs, amphotericin B
and miltefosine, with EC50 values correlating well with published values. This assay has been used, in parallel with enzyme
activity data and direct assay on isolated extracellular amastigotes, to test lead-like and hit-like inhibitors of Leishmania N-
myristoyl transferase (NMT). These were derived both from validated in vivo inhibitors of Trypanosoma brucei NMT and a
recent high-throughput screen against L. donovani NMT. Despite being a potent inhibitor of L. donovani NMT, the activity of
the lead T. brucei NMT inhibitor (DDD85646) against L. donovani amastigotes is relatively poor. Encouragingly, analogues of
DDD85646 show improved translation of enzyme to cellular activity. In testing the high-throughput L. donovani hits, we
observed macrophage cytotoxicity with compounds from two of the four NMT-selective series identified, while all four
series displayed low enzyme to cellular translation, also seen here with the T. brucei NMT inhibitors. Improvements in
potency and physicochemical properties will be required to deliver attractive lead-like Leishmania NMT inhibitors.
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Introduction
The Leishmaniases, together with Human African Trypanoso-
miasis (HAT) and Chagas disease, are caused by kinetoplastid
parasites of the TriTryp group (Leishmania spp., Trypanosoma
brucei and T. cruzi respectively [1–3] and described as neglected
tropical diseases [4]. All of these infections are diseases of poverty
and cause severe impact, as measured in disability adjusted life
years (DALY), in endemic countries (91 in total for the
Leishmaniases, including countries in east and northern Africa,
the Middle East, the Indian sub-continent and Central and South
America [3]). They have also received limited funding for research
and development of new drugs [4] although there are currently
‘‘repurposed’’ drugs in clinical or preclinical trials for all three
disease groups e.g. fexinidazole for visceral leishmaniasis (VL) and
HAT (acute and CNS stages) [5,6]; the antifungal lanosterol-14
alpha-demethylase inhibitors, posaconazole [7] and E1224 (a
prodrug of ravuconazole [8,9]), for Chagas disease (see [4] and
www.dndi.org/ for further details). Despite this recent encourag-
ing progress, there is an urgent need to develop more potential
therapeutics and especially, to identify new chemical entities which
are orally available and fast acting for the treatment of these
diseases. The aim is to cure with a single oral daily dose over a 10
day course in the case of VL and HAT, a challenging target-
product profile particularly for the intracellular (amastigote)
Leishmania parasite in the host.
Small molecule screens with Leishmania spp. have often been
performed with the easily cultured but less clinically-relevant
extracellular insect (promastigote) form of the parasite [10–13].
Axenic amastigotes, adapted to replicate at acidic pH and elevated
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temperature as extracellular parasites, are also used as a screening
resource [14,15] but are not ideal as they are not derived from the
parasitophorous vacuole (PV), the intracellular compartment in
which amastigotes reside within host cells [16]. Indeed, the
differing gene expression and proteomic profiles presented by
promastigotes, axenic amastigotes and intracellular amastigotes of
several Leishmania species suggest differing molecular profiles
during parasite stage differentiation. For example, the mRNA
expression profiles of L. mexicana promastigotes and axenic
amastigotes are remarkably similar whereas when either is
compared to the mRNA profile of lesion-derived amastigotes,
different mRNAs are significantly up- or down-regulated [17].
Similarly, analysis of global mRNA expression profiles of L.
infantum axenic and intracellular amastigotes isolated from
cultured human (THP-1) macrophages reveal very few differen-
tially expressed genes in common between the stages [18]. At the
protein level, comparison of promastigotes with intracellular
amastigotes in L. mexicana reveals several proteins upregulated
solely in amastigotes, including enzymes linked to respiration/
energy metabolism, fatty acid metabolism and protein synthesis,
and proteins involved in stress responses [19]. Upregulated fatty
acid metabolism has also been described in comparisons of lesion-
derived L. mexicana amastigotes and dividing promastigotes [20].
These observations confirm that small compound testing should
ideally be focused on the clinically-relevant parasite stage, the
intracellular amastigote. This conclusion is supported by a recent
study comparing compound efficacy against extracellular promas-
tigotes and intracellular amastigotes; only a small number of those
compounds active against the extracellular life cycle stages were
also active against the intracellular stage [21]. In addition,
progressing a promastigote screening cascade towards intracellular
screening has been shown to not only identify false positives but
also exclude compounds that are active against the relevant
intracellular stage [22]. It is possible that the study design may
have selected for compounds active against differentiating
parasites rather than true intracellular amastigotes in this case;
compounds were added immediately after removing free parasites
from macrophages infected over a period of 4 h with L. donovani
promastigotes, a stage at which amastigote differentiation would
not have been complete. As an additional complication,
compounds that are active against one Leishmania species may
not be active against another, if the observed differences in gene
expression profiles [23] are reflected in their proteomes and
metabolomes [24,25].
High-throughput image-based phenotypic screens of intracellu-
lar amastigotes have gained support as the current preferred
approach for drug discovery against Leishmania spp. [21,22] and
undoubtedly provide a superior approach for screening small
compounds and conducting lead-optimization. However, sophis-
ticated imaging resources are not readily available in many lab
settings, preventing widespread adoption of these techniques. In
addition, some image-based assays rely on genetically-modified
parasites carrying a selectable marker, a feature that can
compromise the identification of new compounds by conferring
resistance itself, as reported for neomycin and paromomycin in
Saccharomyces cerevisiae [26]. The generation of mutants without
selectable markers should overcome this problem [27]. The
expression levels of fluorescent or bioluminescent reporters
encoded on episomes is dependent on their episomal copy number
but this can also vary in a clonal population [28], potentially
affecting the read-out to determine the compound efficacy.
Similarly, genetic modification of parasites might change their
biological properties and subsequently, their sensitivity to test
compounds [29].
Jain and colleagues [30] recently approached the lack of a non–
image based method for intracellular amastigote screening by
developing an assay in which L. donovani promastigotes were used
to infect cultured THP-1 macrophages, differentiated amastigotes
subsequently released by SDS lysis and, following transformation
back to promastigotes and growth for two days, quantified using
Alamar blue. In parallel work, driven by the need to advance a
specific drug development project for the leishmaniases, we have
adopted a similar assay, although using clinically-relevant
amastigotes for infection of bone marrow-derived macrophages
together with saponin lysis, and subsequently validated the method
using the gold standard drugs against VL, amphotericin B and
miltefosine.
Utilising this assay, we have extended work on the development
of myristoyl-CoA:protein N-myristoyltransferase (NMT) as a
promising candidate for the development of anti-kinetoplastid
drugs [31–34]. In collaboration with Pfizer, we recently published
the results of a high-throughput screen against L. donovani NMT
that resulted in the identification of four chemically diverse and
selective series [35]. Here, we present results generated with the
novel NMT inhibitors identified in the Pfizer screen [35], together
with several T. brucei NMT inhibitors [36,37]. Several of the latter
compounds were reported to have similar activity against L. major
NMT and we have also found them to be potent inhibitors of L.
donovani NMT. Structural biology studies on the compounds
derived from the Pfizer screen have been published recently [38];
structure-activity-relationships and synthetic details are being
published separately [39].
Materials and Methods
Animals and parasites
BALB/c mice were obtained from Charles River (Margate,
UK). Rag-22/2 mice were bred in-house, housed under specific
pathogen-free conditions and used at 6–12 weeks of age. The
Ethiopian strain of Leishmania donovani (MHOM/ET/67/HU3,
also known as LV9) was maintained by serial passage in Rag-22/2
Author Summary
We have developed an assay for screening test com-
pounds for their ability to kill intracellular amastigotes of
Leishmania parasites, causative agents of human leish-
maniasis. The assay is based on freeing amastigotes from
infected macrophages by mild detergent lysis and mea-
suring the number of parasites following their extracellular
replication by a fluorescence-based method. The validity of
the assay has been confirmed using the gold standard
drugs, Amphotericin B and Miltefosine, which kill parasites
at highly reproducible concentrations. Our results show
that this assay is easily transferable between laboratories,
can be adapted to specific applications and used to test
any parasite species or strain, and does not rely on
genetically-modified parasites. These features will enable
its use in screening isolates taken directly from patients,
vectors or reservoir hosts. We used this assay, in parallel
with enzyme activity data, to test lead-like and hit-like
inhibitors of a validated target enzyme, Leishmania N-
myristoyltransferase (NMT). Compounds from two of four
newly-identified Leishmania NMT-selective hit series dis-
played host cell cytotoxicity, while all four series displayed
low translation of enzyme to cellular activity in analysis of
intracellular parasite viability. Improvements in potency
and physicochemical properties will be required to deliver
attractive lead-like Leishmania NMT inhibitors.
Screening Intracellular Leishmania
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mice. Amastigotes were isolated from infected spleens by
homogenization and saponin lysis, as previously described [40].
Mice were infected with 36107 L. donovani amastigotes
intravenously (i.v.) via the tail vein in 200 ml of RPMI 1640
(GIBCO, Paisley, UK). All experiments were approved by the
University of York Animal Procedures and Ethics Committee and
performed under UK Home Office licence (‘Immunology and
Immunopathology of Leishmaniasis’ Ref # PPL 60/4377).
In vitro infection
Macrophages (BMDM) were differentiated from bone marrow
of 6–8 weeks old female BALB/c mice as described previously [41]
and plated out at 4.26104 cells/per well in 96-well plates.
BMDMs were adhered for at least 4 h and infected overnight at a
multiplicity of infection of 15 with freshly isolated L. donovani
amastigotes (see above). BMDMs were maintained in DMEM
supplemented with 4 mM L-Glutamine (both GIBCO, Paisley,
UK) and 4% L929-cell conditioned medium. All experiments were
performed at 37uC and 5% CO2.
Reference compounds and determination of parasite
burden
The anti-leishmanial reference drugs amphotericin B (Fungi-
zone, kindly provided by Vanessa Yardley, London School of
Hygiene and Tropical Medicine) and miltefosine (Sigma,
#M9198) were used, the former reconstituted according to the
manufacturer’s instructions. Miltefosine was dissolved in deionised
water. Compounds were prepared at 26 concentration in a 7-
point threefold dilution series and tested in triplicate. The highest
concentrations used were 30 mM (miltefosine) and 1.2 mM
(amphotericin B). Infected macrophages were incubated with the
compounds for 72 h. Infected and uninfected cells were then
washed twice with DMEM before lysis with 100 ml 2 mg?ml21
saponin in DMEM for 5 min at room temperature (RT). Lysis was
stopped by addition of 100 ml undiluted fetal calf serum (FCS).
Plates were centrifuged at 22006g (Heraeus Multifuge 3SR
Plus) for 5 min at RT and the medium carefully removed. For all
manipulations of this type, as much as possible of the supernatant
was carefully but swiftly removed with an 8-channel pipette,
placing the pipette tips into the corners of the wells in an angled
plate and quickly aspirating until virtually all liquid was removed.
Fresh medium was quickly replaced to prevent cells drying out. In
this case, 200 ml RPMI 1640 medium (#22409-015, GIBCO,
Paisley, UK) supplemented with 20% heat-inactivated FCS,
100 mM adenine, 20 mM 2-[N-morpholino] ethanesulphonic acid
(pH 5.5), 5 mM hemin, 3 mM biopterin, 1 mM biotin, penicillin
(100 U/ml) and streptomycin (100 mg/ml) were then added, at
final pH 6.7, and incubation continued at 26uC. After 96 h, 20 ml
Alamar blue (Trek Diagnostics) was added and incubation
continued at 26uC for a further 6 h or until the Alamar blue
was reduced sufficiently (as determined visually by its conversion
from oxidised state blue to reduced state pink). Further reduction
was stopped by addition of 20 ml 8% formaldehyde solution.
Fluorescence was measured using a POLARstar Optima (BMG
Labtech) plate reader (ex. 544 nm, em. 590 nm) with the lid
removed.
Drug dilutions for the extracellular assays were prepared in the
same way but in supplemented RPMI medium. Assays were
performed in triplicate with 46105 L. donovani amastigotes
(freshly isolated as described above) per well per 96-well plate,
plating 100 ml of parasite suspension per well first and then adding
the drug dilution to be tested. Sealed 96 well plates were then
placed at 26uC. After 72 h, 20 ml Alamar blue was added and the
fluorescence measured 6 h later.
Host cell cytotoxicity was determined by seeding out as above;
compounds were added at 26concentration in a 7-point threefold
dilution series and tested in duplicate. After 72 h, 1/10 vol Alamar
blue was added and the fluorescence measured 6 h later. To
determine LD50 values, the following highest concentrations were
used based on the L. donovani NMT potency or, if necessary,
lowered due to compound insolubility at a higher concentration:
150 mM – IMP-0000556; 90 mM - IMP-0000197, DDD100887
and DDD86211; 45 mM - DDD85646, IMP-0000083, IMP-
0000195.
Drug activities were determined by calculating the percentage
of the measured fluorescence values of treated compared to
untreated cells. GraphPad Prism (ver. 5) was used to plot dose
response curves, to calculate EC50 values by non-linear regression
with variable slope, to calculate correlation coefficients of curves
and for statistical analysis. Table 1 lists the mean EC50 values and
standard deviation for each experiment, calculated using Graph-
Pad Prism (ver. 5).
Results
Establishing the L. donovani amastigote assay
To avoid reliance on fluorescent/luminescent parasites, sophis-
ticated microscopy equipment or counting parasites on Giemsa-
stained slides, we developed an assay for drug-testing similar to
that already described [30] in which surviving parasites are
released from infected macrophages, allowed to differentiate into
promastigotes and then enumerated. In our assay, bone marrow-
derived macrophages are infected with L. donovani amastigotes
and incubated for 72 h in the presence or absence of test or
control compounds. Macrophages are then subject to conditional
lysis with saponin, a milder treatment than the 0.05% SDS used by
Jain et al. [30], followed by incubation for up to 4 days in
promastigote medium at 26uC. During this time, the amastigotes
trapped in the macrophage debris transform to promastigotes and
these break free (due to flagellar motion) and commence
replication. In the presence of Alamar blue, its active component,
resazurin, is then reduced to resorufin by the metabolically active
parasites. This reduction is directly dependent upon parasite
numbers (see Fig. 1). The transformation from amastigote to
promastigote and subsequent proliferation is necessary to amplify
the signal obtained by the Alamar blue reduction. This allows
determination of the parasite burden - that is, the respective
parasite load on the day of lysis, assuming an equal proliferation
rate irrespective of initial parasite numbers.
Firstly, a direct correlation was established between parasite
numbers after transformation and the resulting fluorescence from
the reduced Alamar blue. This was done by seeding freshly
isolated splenic amastigotes in supplemented RPMI into a 96-well
plate. Alamar blue was added and the parasites incubated at 26uC.
Transformation occurred over time and the resulting promasti-
gotes started to replicate, resulting in Alamar blue reduction.
Fluorescence was measured every 24 h to monitor this reduction
of the dye relative to the parasite numbers per well. As shown in
Fig. 1, the reduction of Alamar blue was directly proportional to
the numbers of viable cells over at least two orders of magnitude
(initial cell numbers 104–106) for at least 72 h (Fig. 1). This finding
confirms the assumption that the proliferation rate is equivalent
between samples, irrespective of the initial number of parasites.
Linearity was tested with up to 106 L. donovani amastigotes
(Fig. 1), which in our hands reflected an idealized condition as
these cell numbers were not achieved upon conditional lysis of the
macrophages. This correlation should however be verified prior to
implementation of this assay as it is dependent on the parasite
Screening Intracellular Leishmania
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strain/s as well as the macrophage cell lines used. It is important to
stress that the protocol described here is only evaluating the anti-
leishmanial activity of compounds against the intracellular lifecycle
stage. Upon lysis and freeing of amastigotes, the transformation to
promastigotes is not affected by the compounds as these are no
longer present at this stage of the protocol.
Secondly, uninfected and infected macrophages were lysed with
varying amounts of saponin (2, 2.5 and 3 mg?ml21), a milder
detergent compared to SDS, dissolved in non-supplemented
DMEM. As shown in Fig. 2, in our hands amastigotes were most
effectively freed from macrophages, with limited survival of the
latter, using 100 ml of 2 mg?ml21 saponin and incubation for
5 min, prior to lysis termination by addition of 100 ml of undiluted
FCS. Analysis using two-way ANOVA with Bonferoni post test on
the fluorescence intensity difference between infected and unin-
fected macrophages showed that significantly more amastigotes
were freed from macrophages when using 2 mg?ml21 saponin
compared to higher concentrations; there was no significant
difference between 2.5 and 3 mg?ml21 saponin lysis. Using this
lysis method, a 5-fold greater signal from freed amastigotes over
live macrophages was achieved. To determine the lysis efficiency
(i.e. the background level) and to compensate for inter-experiment
variation, uninfected macrophages were monitored in all exper-
iments carried out using this method.
Validating the amastigote assay with known drugs
To confirm the efficacy of this assay, that uses primary
macrophages infected with freshly isolated amastigotes rather
than a macrophage-like cell line infected with promastigotes [30],
dose response curves and EC50 values were generated for
amphotericin B and miltefosine (the gold standard drugs for the
treatment of VL [4]). The EC50 values were 30 nM and 1.38 mM
respectively, correlating well with the data described by other
groups [42–44]; see Fig. 3 and Table 1.
Amphotericin B and miltefosine were also tested on amastigotes
freshly isolated from mouse spleens, thereby avoiding any in vitro
macrophage infection. These assays, referred to as the ‘‘extracel-
lular assays’’ hereafter, resulted in EC50 values of 50 nM and
7.85 mM respectively (dose response curves not shown, Table 1)
and were also in good alignment with values described elsewhere
[43,45].
Testing small compounds inhibitory to NMT
NMT inhibitory compounds were tested against L. donovani
amastigotes in both the extracellular and intracellular assays
described above. The focus was on the small compounds identified
by high throughput screening against L. donovani NMT and
found to have selectivity over the human NMTs (Fig. 4B) [35]. In
addition, we profiled several examples from a series of T. brucei
NMT inhibitors identified by the Dundee Drug Discovery Unit,
since this series has been reported to also inhibit L. major NMT
[36]. The original small molecule showing the highest activity
against the NMT of bloodstream stages of T. brucei in vivo
(DDD85646; Fig. 4A), identified by Frearson et al. [31], and two
further compounds derived from this TbNMT inhibitor [37]
(Fig. 4A, Fig. 5 and Table 2) were resynthesized and tested. The
Table 1. Activity of gold standard drugs after 3-day treatment against intra- and extracellular L. donovani amastigotes.
EC50 ± SD intracellular L. donovani amastigotes EC50 ± SD extracellular L. donovani amastigotes*
Amphotericin B 3069 nM 50611 nM
Miltefosine 1.3860.06 mM 7.8560.5 mM
*Assay was set up with amastigotes isolated from spleens of infected Rag22/2mice with subsequent incubation at 26uC. All assays were run in triplicate with biological
repeats (intracellular amphotericin B, n = 4; intracellular miltefosine, n = 3; extracellular amphotericin B, n = 3; extracellular miltefosine, n = 2).
doi:10.1371/journal.pntd.0003363.t001
Fig. 1. Linear correlation of the number of L. donovani amastigotes and the reduction of Alamar blue. L. donovani amastigotes were
isolated from the spleen of an infected Rag-2 2/2 mouse. Up to 106 (A) or 105 (B) parasites were suspended in 200 ml/well in supplemented RPMI,
Alamar blue was added and the plate incubated at 26uC. At the indicated time points, the fluorescence per well was determined and plotted over the
initial number of parasites/well. The correlations between Alamar blue conversion and the initial parasite numbers are highly significant: P,0.0001 as
shown by linear regression analysis (R224h– 0.9979, R248h – 0.9991, R272h – 0.9984).
doi:10.1371/journal.pntd.0003363.g001
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activities of all of these resynthesised compounds were confirmed
by testing on purified L. donovani NMT (IC50 values in Tables 2
and 3), using the assay described by Goncalves and colleagues
[46]. The figures generated were in agreement with those reported
previously [35,36]. The compounds were then progressed to
evaluation of their cellular activity.
Hit compounds derived from the high-throughput screen were
resynthesized and their enzyme activity confirmed in our assays. A
range of different profiles were observed in the cellular assays with
IMP-0000556 showing no cellular activity up to 30 mM whereas
IMP-0000197 gave an EC50 of 16 mM in the extracellular assay.
IMP-0000195, the most potent LdNMT inhibitor from the HTS
screen, had a moderate cellular activity (EC50 12 mM) but was
equally toxic to macrophages. Of the HTS-derived compounds,
IMP-0000083 (a close analogue of the Pfizer hit) has the most
promising profile. Although ,4-fold less potent in its inhibition of
LdNMT than IMP-0000195, the activity difference was reduced at
the cellular level, while showing no toxicity to host cells (Table 3).
The re-synthesised version of the original T. brucei NMT
inhibitor, DDD85646, as well as derivatives thereof (DDD86211
and DDD100887), were tested in both the extracellular assay and
the intracellular assay (Fig. 5). DDD85646 was the most potent
LdNMT inhibitor in the enzyme assay, followed by DDD86211
and DDD100887. However, at the cellular level, DDD85646 was
the least active (EC50 8 mM in the extracellular amastigote assay).
The cellular activity of DDD86211 against extracellular amasti-
gotes (EC50 180 nM) was impressive, while DDD100887 was also
effective (EC50 660 nM). All three compounds also had some
activity against intracellular L. donovani amastigotes (Fig. 5 and
Table 2). However, only compound DDD100887 generated a
genuine dose-response curve with an EC50 value of 190 nM. In
comparison, DDD85646 and DDD86211 caused an initial
concentration-dependent increase in anti-leishmanial activity
followed by a reproducible decrease at 15 mM. At the highest
concentration tested, 45 mM, both compounds exerted a strong
cytotoxic effect and all amastigotes were cleared from the
macrophages (Fig. 5). For both DDD85646 and DDD86211, this
‘‘activity valley’’ was a reproducible effect over successive
experiments.
Discussion
We have developed a robust assay to screen for inhibitory
compounds active against intracellular Leishmania, independent of
automated fluorescent microscopy or the time-consuming count-
ing of parasites on Giemsa-stained slides. It is similar to a
previously reported assay [30] but uses isolated splenic amastigotes
rather than cultured promastigotes for the initial infection of
primary macrophages and subsequent reproducible lysis by the
mild detergent saponin over a 5 min period, rather than harsher
SDS treatment for 30 sec. We have focused on L. donovani as our
test organism here, given its importance as the causative agent of
the most severe form of leishmaniases, but other Leishmania
species and/or host cells could easily be used in this assay format.
Key steps in optimising the assay included determining the best
lysis conditions for parasite release while retaining only marginal
background signal from any surviving macrophages. For the L.
donovani/bone marrow-derived macrophage model used here,
lysis with 2 mg?ml21 saponin in DMEM for 5 min at room
temperature gave the best results, with amastigote integrity
compromised at higher saponin concentrations (Fig. 2). After
Fig. 3. Dose response curves for amphotericin B and miltefosine against intracellular L. donovani amastigotes. Parasites were released
by conditional lysis with saponin from bone marrow derived macrophages of BALB/c mice after 72 h incubation with anti-leishmanial standard drugs.
Using this method, the measured activities of amphotericin B (EC50 29 nM) and miltefosine EC50 (1.45 mM) were reproducible and comparable to
reported values against intracellular L. donovani (43–45). Representative plots for amphotericin B (n = 4) and miltefosine (n = 3) are shown. (R2AmphoB –
0.9905, R2Mil – 0.9963).
doi:10.1371/journal.pntd.0003363.g003
Fig. 2. Release of parasites from infected macrophages in 96-
well plates. Bone marrow derived macrophages were infected
overnight with L. donovani amastigotes. Cells were incubated for a
further 3 days and then treated with DMEM containing the indicated
concentration of saponin. Supplemented RPMI was added to the
released amastigotes and plates were further incubated for 4 days at
26uC before addition of Alamar blue and subsequent measurement of
fluorescence in a plate reader. The survival of freed amastigotes is
dependent on the concentration of saponin used and the time of lysis.
A 5-fold greater signal of reduced Alamar blue from freed amastigotes
over uninfected macrophages was achieved with 2 mg?ml-1 saponin
for 5 min; this concentration was used for all other experiments
performed. All samples were run in triplicate; one representative
experiment is shown. MW, uninfected macrophages; iMW, infected
macrophages. *** denotes P,0.0001 as determined by a two-way
ANOVA.
doi:10.1371/journal.pntd.0003363.g002
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macrophage lysis and centrifugation, the amastigote-containing
supernatant was supplemented with RPMI medium and incubated
at 26uC, triggering amastigote to promastigote transformation and
subsequent parasite proliferation. This second stage of the assay
was critical for amplification of the signal over background; the
number of amastigotes present on the day of lysis was insufficient
to achieve this result. By performing this incubation step, the
resulting signal is dependent on the initial amastigote number as
long as the differentiated promastigotes are in the logarithmic
growth phase (Fig. 1). In our hands, this phase continued for at
least 4 days, by which time the signal was sufficiently amplified to
generate highly reproducible results. While an assay requiring 9
days for completion may be considered non-optimal, this protocol
allows a number of compounds to be tested sequentially (possible
at medium through-put in culture wells) and has the advantage
that counting of parasites is not required rather than the
admittedly more exacting counting of Giemsa-stained amastigotes
in infected macrophages on slides. Thus results between labora-
tories should be subject to less variability. A further advantage of
this method is its lack of dependence on genetically modified
parasites, facilitating compound testing on both resistant and
sensitive parasite field isolates.
We want to highlight that both this assay and the Jain assay [30]
are apparently good alternatives for screening inhibitory com-
pounds active against intracellular Leishmania parasites, being
independent of automated fluorescent microscopy or Giemsa-
staining. Our assay is straightforward to establish, highly
reproducible and has the potential for semi-automation to
facilitate higher through-put screening.
Validation of this assay has been achieved using the anti-
leishmanial gold standard drugs, amphotericin B and miltefosine.
The resulting EC50 values are in good agreement with those
reported against L. donovani elsewhere [42–44] and provide
confidence that the assay can be used successfully to screen new
compounds for activity against Leishmania amastigotes.
To this end, we progressed to testing a number of available
NMT inhibitors, including those with advanced lead-like activity
in T. brucei blood stream parasites, potent inhibitory activity
against L. major NMT [31,36] and the initial hits from the recent
Pfizer HTS screen [35]. These were first tested against purified
recombinant LdNMT to confirm their potency and then tested in
the extracellular model described above, in which isolated splenic
L. donovani amastigotes were incubated in the presence of
inhibitor at 26uC. This method has the advantage of using host-
derived amastigotes as the starting point as opposed to axenic
amastigotes, which differ from intracellular amastigotes [17,18],
especially in their metabolism [18]. Conversely, the model could
be problematic for general compound screening, introducing a
bias towards compounds targeting parasite differentiation or
promastigote replication. The final stage of testing used the new
intracellular assay.
Focusing firstly on the TbNMT inhibitors DDD85646,
DDD100887 and DDD86211 [31,36], these compounds gave
IC50 values of 4.4 nM, 20 nM and 7.3 nM respectively against L.
donovani NMT. However, surprisingly, DDD85646 translated the
least effectively from enzyme to cell, with a sharp drop in potency
against L. donovani extracellular amastigotes, resulting in an EC50
of 8 mM.
Fig. 4. Chemical structures of NMT inhibitors. (A) Resynthesised T. brucei inhibitors identified by the Dundee Drug Discovery Unit as also
inhibiting L. major NMT [31,37]. Results summarized in Table 2. (B) Selective inhibitors identified by high throughput screening against L. donovani
NMT [35]. Results summarised in Table 3.
doi:10.1371/journal.pntd.0003363.g004
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Fig. 5. Cellular activity of compounds with good potency in the extracellular but varying potency in the intracellular model. All three
compounds tested showed cellular activity on the intracellular and extracellular L. donovani amastigotes. When tested against intracellular
amastigotes, only DDD100887 generated a reproducible dose-response curve. It was not possible to generate dose-response curves for DDD85646
and DDD86211 as both compounds resulted in an reproducible ‘‘activity valley’’ at higher concentrations before resulting in complete killing of the
parasites at the highest concentration tested (see text for details). One representative experiment is shown for each compound. The correlation
coefficients for the extracellular amastigotes were R2.0.98, with almost all very close to or .0.99. The correlation coefficient for intracellular
DDD100887 is R2 0.9212.
doi:10.1371/journal.pntd.0003363.g005
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Compounds DDD100887 and DDD86211 were more effective,
generating EC50 values of 660 nM and 180 nM, respectively.
Thus, the chemical modifications introduced into these com-
pounds (moderation of their basicity or reduction in the number of
hydrogen bond donors) resulted in an improved translation of
enzyme to cell activity, perhaps due to better cellular penetration
as compared to DDD85646 [36]. These results were partially
reflected in the intracellular model data but the compounds were
,10-fold (in the case of DDD100887) less active when compared
to the purified NMT enzyme, the cellular target. This was the only
compound for which a genuine dose-response curve could be
plotted and an EC50 value calculated. Both DDD85646 and
DDD86211 did not result in an expected dose-response relation-
ship, precluding the EC50 calculation. Initially the compounds
displayed cytotoxic effects before an ‘‘activity valley’’ was detected
at higher concentrations. Both compounds were cytotoxic, at
45 mM, however, with all amastigotes cleared from the macro-
phages at this compound concentration. We currently have no
rational explanation for the occurrence of this activity valley.
The remarkably good translation between NMT activity and
cellular activity of DDD85646 observed in T. brucei blood stream
parasites [31] was not observed for L. donovani in either the extra-
or the intracellular model. Procyclic (insect) stages of T. brucei
parasites were also much less sensitive to DDD85646 (pers. comm.
H.P. Price), perhaps due to the different rates of endocytosis
between the two parasite stages (with bloodstream trypanosomes
having an unusually high rate [47–49]. Endocytosis rates are also
slower in Leishmania species when compared to the bloodstream
form of T brucei, although recent data suggest up-regulated
endocytosis in L. mexicana amastigotes [50]. A similar lack of
translation from enzyme to cellular activity has been reported for
L. major CRK3 kinase inhibitors [51,52], perhaps reflecting more
general problems in targeting amastigote stages of Leishmania.
These might include uptake and delivery of compounds into the
macrophage, their chemical modification as a result of the acidic
environment of the parasitophorous vacuole and/or their export
from the phagolysosome via diffusion or active transport.
The second set of compounds tested in this study, derived from
the Pfizer screen [35] were no better than the optimised Dundee
derivative compounds in the extracellular amastigote assay.
However, this analysis aided identification of issues to be addressed
in a hit-to-lead development programme. Thus, IMP-0000195
(IC50 76.5 nM, EC50 12 mM) was the best enzyme inhibitor but
also showed host cell toxicity and no selectivity. IMP-0000556 did
not result in any leishmanicidal activity, probably due to
insufficient potency - this is the compound with the least activity
in the enzyme assay. More promisingly, IMP-0000083 and IMP-
0000197 showed moderate cellular activity in the extracellular
assay with no host cell cytotoxicity up to at least 45 mM. However,
these two compounds showed no activity in the intracellular assay.
Clearly, more work is required to improve both the potency and to
optimise the physicochemical properties of these initial hits to
improve cellular activity, developments that are currently in
progress.
In summary, we report a robust assay for screening compounds
against intracellular Leishmania amastigotes that should enable
others to screen natural product or other libraries for identification
of compounds active against the clinically-relevant life cycle stage.
Leishmania NMT inhibitors are in early development but the
compounds described here show good potential for further
progression with respect to selectivity and cellular potency. In
addition, methods that enhance compound delivery into both the
parasitophorous vacuole and the intracellular parasites require
further investigation. An optimised delivery system might increase
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the therapeutic ‘‘window’’, thereby greatly improving the modest
selectivity or potency observed so far.
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